A Phase I Study of MRTX849 and TNO155 in Advanced Cancers with the KRAS G12C Genetic Mutation


Full Title

A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation


The purpose of this study is to find the highest doses of the investigational drugs MRTX849 and TNO155 when they are given together in patients with metastatic non-small cell lung cancer (NSCLC) that contains a genetic mutation called KRAS G12C mutation. This mutation sends signals to cancer cells that tell them to divide, which is how cancer cells grow and spread.

MRTX849 targets the KRAS G12C mutation and prevents it from sending signals to cancer cells. TNO155 blocks a protein called SHP2, which sends signals to cancer cells that have KRAS mutations. Researchers believe that drugs that target KRAS G12C (such as MRTX849) work better when SHP2 is blocked. Both MRTX849 and TNO155 are taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic NSCLC that persists despite prior treatment and contains the KRAS G12C mutation.
  • At least 2 weeks must pass between the completion of prior therapy and receipt of the study treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Kathryn Arbour at 646-608-3792.